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Significant advances have been made in developing novel therapeutics for cancer treatment, and
targeted therapies have revolutionized the treatment of some cancers. Despite the promise, only
about five percent of new cancer drugs are approved, and most fail due to lack of efficacy. The
indication is that current preclinical methods are limited in predicting successful outcomes. Such
failure exacts enormous cost, both financial and in the quality of human life. This Primer explores
the current status, promise, and challenges of preclinical evaluation in advanced mouse cancer
models and briefly addresses emerging models for early-stage preclinical development.Explosion of Cancer Therapies and Challenges to
Clinical Success
Ever-increasing knowledge of cancer biology has yielded count-
less possibilities for diagnostic and therapeutic strategies
(Figure 1), while at the same time revealing enormous disease
complexities that challenge clinical success. Such challenges
include tumor microenvironment complexities, intra- and inter-
tumor molecular and biological heterogeneity, systemic and
tumoral immune and metabolic response heterogeneity, and
the ability of drug-resistant stem-like cancer-initiating cells to
repopulate treated cancers (Pattabiraman and Weinberg,
2014). Too often, experimental targeted therapies designed to
assimilate known disease complexity have proven ineffective,
only to highlight the limitations in our understanding. In contrast
to most experimental targeted therapies, encouraging advance-
ments have been made using a number of cell-based and
targeted immunotherapies, which have produced sustained re-
sponses in patients (Page et al., 2014). However, only a fraction
of patients respond to these therapies.
Over the last decade, cancer classification has shifted from
relying solely on histiopathologic properties to including key
molecular attributes that can predict therapeutic outcomes.
That certain molecular aberrations are targets for effective ther-
apy first led to clinical practice in 1995 after a leukemia (APL)
bearing the PML-RARa translocation was shown to be sensitive
to retinoic acid (tretinoin) (Quignon et al., 1997), which targets the
RARa component to effect leukemic cell differentiation. Soon
thereafter, Herceptin (a Her2 inhibitor) was approved for treating
Her2+ breast cancer (1998), and Gleevec (a BCR-ABL inhibitor)
was approved for CML treatment (2001). These highly effective
drugs rapidly became the standard of care. Although these suc-
cesses establish the promise of targeted therapies, most at-
tempts to attain similar results targeting knownmolecular drivers
have failed, and the reasons are often elusive because of human
research limitations. Some general principles have been recog-
nized that emphasize the need for preclinical platforms approx-imating human cancers. For example, in each of the noted suc-
cesses, single potent cancer drivers present in a significant
fraction of patient malignancies were targeted; however, when
a minor fraction of patients are responsive, all-comer clinical trial
data may mask the responders. This was first demonstrated in
non-small-cell lung cancer (NSCLC) patient trials that initially
failed to show significant responsiveness to EGFR-targeted tyro-
sine kinase inhibitors; however, the 10% of patients whose tu-
mors actually harbored activating EGFR mutations were
uniquely sensitive (Lynch et al., 2004; Paez et al., 2004). Now,
screening of lung cancers for such mutations prior to therapy
is routine practice. Lung cancer is the most prevalent US cancer;
if limited to clinical trials, accurate identification of therapies
effective in a fraction of less-common cancer types may not be
possible. Nonetheless, when a specific target was known, strat-
ification of patients has identified additional effective therapies,
such as inhibitors for BRAFmutant melanomas and ALK translo-
cation-positive NSCLCs (Pagliarini et al., 2015). Unfortunately,
patients treated with single targeted therapies inevitably relapse
with cancers that are resistant to the original drug.
Another challenge in targeting single drivers is the feedback
response upon molecular network disruption that prevents effi-
cacyorcauses increasedseverity.Understandingsuchmolecular
responses can aid in the discovery of more effective combination
therapies. In addition, unbiased molecular queries are showing
promise in identifying signatures that correspond to prognosis
and/or therapeutic outcomes. For example, in some cases,
unique transcriptomesignaturesstratify cancers intodistinct ther-
apeutic and/or prognostic categories and thus improve patient
management (e.g., Garraway, 2013). Thus far, this approach
has been used primarily for determining which patients require
aggressive chemotherapy treatment, hence reducing the fre-
quency of over-treatment. Oncotype DX and FDA-approved
MammaPrint tests, both based on distinguishing transcriptome
signatures, are now utilized in the clinic to identify the low risk
breast cancer patients to be excluded fromaggressive treatment.Cell 163, September 24, 2015 ª2015 Elsevier Inc. 39
Figure 1. Targeting the Tumor and Its
Microenvironment
Genetic alterations produce oncogenes that drive
signaling pathways in cancer cells facilitating
survival and growth. However, tumor cells also
cooperate with stromal cells, including vessels,
fibroblasts, and various immune cells, to acquire
growth factors, an energy supply and protection
from host defenses. These key autonomous and
stromal mechanisms constitute potential thera-
peutic targets both locally, and for immune cells
also in the circulating blood and distant immune
organs, as shown by indicated numbers. (1) Can-
cer cell growth driven by an aberrant kinase
(‘‘Driver Gene’’) can be targeted by small-molecule
inhibitors. (2) Oncogenic signaling promoting un-
controlled cell cycling can be disrupted (e.g., anti-
metabolites, anti-microtubule agents, DNA-
damaging agents). (3) Tumor growth requires
development of new vasculature for enhanced
nutrient demands, which can be blocked by anti-
angiogenic agents. (4 and 5) Growth of cancer
cells stimulated by release of either host-derived
hormones (4, green arrow) or growth factors (5,
blue arrows from blood vessels, fibroblasts,
macrophages, and myeloid-derived suppressor
cells [MDSC]) can be targeted by hormone in-
hibitors (e.g., anti-hormones or biosynthesis in-
hibitors) or growth factor receptor inhibitors,
respectively. (6 and 7) Tumor cells can shift the
inflammatory response to an immunosuppressive
mode (e.g., activation of CTLA-4 and PD-1 in
T cells or PD-L1 in cancer cells). The immunosuppressive environment can be reversed via treatment of immunomodulatory cytokines (6, modulator sign; e.g., IL-
2, IL-15) or immune checkpoint inhibitors (7, modulator sign; e.g., anti-CTLA-4, anti-PD-1, or anti-PD-L1), resuming anti-cancer activity of T cells. Left inset: key
for therapeutic modes. Right inset: targeting agents. (Artwork adapted from design by Jonathan Marie).Yet, accuracy is not optimal, and numerous challenges currently
prevent broad implementation ofmolecular signature diagnostics
(van’t Veer and Bernards, 2008). Additionally, the hope is that
molecular signatures can be identified via unbiased compound
ormolecular screens that will dictate specific effective treatments
even when the targets are unknown.
Thus, although clearly impactful, the use of cancer molecular
constitution to guide clinical practice is in its infancy, and
research to identify parameters that hone specificity and
improve accuracy is ongoing. If confined to human research,
achieving maximum effectiveness is likely impossible due to
low frequencies of each molecular subtype within most cancers
and limitations associated with clinical trials. More challenging is
understanding the impact of complex and varied inherited ge-
netic constitution on clinical outcomes with subsequent conver-
sion to clinical practice (Hood and Friend, 2011). In this regard,
the sophistication of complex trait evaluation in mice using the
collaborative and diversity crosses may offer a path to discovery
(Churchill et al., 2004; Svenson et al., 2012).
The above summary provides only a cross-section of the ther-
apeutic and diagnostic possibilities currently under investiga-
tion, and the reader is referred to current review articles for
more comprehensive information (Chin et al., 2011; Hood and
Friend, 2011; Yap et al., 2013). Ultimately, the current limitation
to improving cancer patient care within reasonable timeframes
may not be the availability of potentially efficacious therapies;
rather, a major blockade is the lack of a fully developed and inte-
grated set of reliable preclinical technologies that can navigate
complex variables in therapeutic responses and diagnostic ac-40 Cell 163, September 24, 2015 ª2015 Elsevier Inc.curacy. To optimally develop efficacious therapies, preclinical
research must utilize a diversity of models that collectively incor-
porate the biology and genetics dictating therapeutic outcomes
for specific cancers, and yet achieve sufficient throughput. Here
we summarize the value and constraints of mouse cancer
models, highlight recent progress indicating promise, summa-
rize non-mammalian and ex vivo preclinical models, and explore
the needs for, and challenges to, developing robust multi-
faceted preclinical platforms for routine use.
Mouse Cancer Models in Preclinical Research
Murine cancer models designed to capture the complexities of
human cancers currently offer themost advanced preclinical op-
portunity for navigating diverse mechanisms that provide ratio-
nale for therapeutic development (Van Dyke and Jacks, 2002).
One approach is to probe pathobiology mechanisms to design
effective treatments by perturbation with molecularly targeted
therapies (Olive and Tuveson, 2006). Additionally, the models
are being used/developed as preclinical efficacy determination
platforms to guide clinical trial designs (Singh et al., 2012). How-
ever, the application of complex cancer models to clinical
research directives is an emerging science, currently executed
in individual settings and with limited resources. Significant
research, ideally in a team-directed, multi-institutional effort, is
required to hone existing technologies into integrated preclinical
workflows to optimally accelerate positive clinical outcomes.
A variety of approaches to mouse cancer modeling are now
available (Figure 2), and each has strengths and weaknesses
(Table 1). Here, we address the limitations of standard Cell
Figure 2. Current State of Preclinical Can-
cer Modeling
Preclinical mouse models can be defined ac-
cording to the species source of tumor, how it is
created, and how it is manipulated. (Upper panel)
Tumors derived from human patients, and other
non-murine species, can be directly transplanted
into immunocompromised mice to form patient-
derived xenograft (PDX) models; PDXs can also be
established from circulating tumor cells (CTCs).
Alternatively, these same tumors can produce
established cell lines maintained in vitro as cell
cultures, and transplanted into immunocompro-
mised mice to form cell line-derived xenograft
(CDX) models. Since the hosts of these tumors
need to be immunocompromised, they are useful
only for testing the efficacy of chemotherapeutics
(Chemo) and targeted small-molecule inhibitors
(Targeted). Xenograft models derived from canine
patients also belong to this category, but are not
shown here. (Lower panel) Mice can be en-
gineered to generate tumors of human relevance
with respect to histopathology, etiology, and mo-
lecular wiring. Offspring of such genetically en-
gineered mice (GEM) can serve directly as pre-
clinical models themselves, in which case the tumor is treated at its precise point of origin. Notably, model building can be streamlined by using non-germline
approaches, one of which is to genetically modify ES cells and study the arising chimeric mice without time-consuming breeding schemes. Alternatively, tumors
harvested fromGEMs can be transplanted and expanded into fully immunocompetent syngeneic hosts, forming GEM-derived allograft (GDA) models. Syngeneic
models allow preclinical studies of not only chemotherapeutic and small-molecule drugs, but also of all varieties of immunotherapeutic agents (Immuno).line-Derived Xenograft (CDX) models, describe genetically and
biologically engineered mouse cancer models [Genetically
Engineered Mouse (GEM), GEM-Derived Allograft (GDA),
Patient-Derived Xenograft (PDX) models], review values and
constraints, and highlight recent progress. Thus far, results indi-
cate promise in understanding cancer pathobiology and in the
enhancement of clinical efficacy prediction, but also underscore
the need for further development to achieve consistent reliability.
Traditional Mouse Models in Therapeutic Development
Historically, preclinical mouse models have co-evolved with
cancer therapy development (Figure 3). The earliest models
were built through transplantation of murine tumors into immu-
nocompetent host mice (DeVita and Chu, 2008; Talmadge
et al., 2007). These early mouse-in-mouse isograft models
served as workhorses for drug screening during the 1960s and
1970s, and were successful in identifying a number of effective
cytotoxic drugs such as vincristine and procarbazine (DeVita
and Chu, 2008). During the 1980s, researchers explored mecha-
nisms of metastasis using selected murine and human tumor cell
lines. A series of investigations by Fidler and colleagues demon-
strated that metastasis is not random but site-selective (Fidler
and Hart, 1982), and that metastatic patterns are injection site-
dependent, supporting the establishment of ‘‘orthotopic’’
models (Talmadge et al., 2007). Since then, cancer therapeutic
development has relied upon the more tractable CDX transplan-
tation models, in which tumors develop after subcutaneous
injection of in vitro-established human cancer cells into immuno-
compromised mice (Figure 2). The cell lines have been selected
over many passages for rapid 2D growth on plastic in serum-
containing media. The NCI60 cell line panel (DeVita and Chu,
2008; Talmadge et al., 2007) provided a valuable resource
from which most CDXs were generated, and recent efforts
have greatly expanded the repertoire (Reinhold et al., 2015).These models are easily established in a wide variety of labora-
tory settings and have been successfully used to identify an
abundance of cytotoxic drugs leading to chemotherapy treat-
ments that still dominate clinical cancer management (Figure 3).
Unfortunately, CDXs have failed to predict human efficacy for
most therapies targeted to cancer-driving proteins (Johnson
et al., 2001), as evidenced by the low FDA approval rate of
5%–7% for targeted therapeutics (Sharpless and Depinho,
2006). With an average time from discovery to clinical practice
of 12 years, at an average estimated cost of $0.5–$2.0 billion
(Adams and Brantner, 2006) and an immeasurable human
price, this low yield forestalls even a goal to chronically manage,
rather than cure, cancers. The observation that most cancer
therapeutics fail in clinical phase II and III efficacy assessment
indicates that current standard preclinical practice inadequately
addresses complex challenges to successful treatment, such
as host immune responses, cancer heterogeneity, and drug
resistance. Consequently, the system cannot be used to opti-
mize a multitude of variables known to influence therapeutic
outcomes, such as combinatorial therapies, dosing schedules,
and drug delivery methods (Al-Lazikani et al., 2012). CDXs
continue to be valuable in identifying non-targeted cytotoxic
agents and in primary assessment of drug toxicity (Teicher,
2006), for analyzing resistance mechanisms (Garraway and
Ja¨nne, 2012) and in triaging potentially effective targeted thera-
pies for evaluation in more representative models.
Mouse Models Designed after Patient Cancers
Mice and humans are believed to have diverged from each other
87 million years ago (Bailey et al., 2013), so naturally there are
numerous significant similarities between the two species, and
also many marked disparities, including differences in immune
systems and drug metabolism. Based on the premise that many
cancers have been cured in mice and not in people, many argueCell 163, September 24, 2015 ª2015 Elsevier Inc. 41
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42 Cell 163, September 24, 2015 ª2015 Elsevier Inc.that mice are inappropriate for use in therapeutic development
(Leaf, 2004). However, it is critical to understand that ‘‘cures’’
have been attained only in CDX models, thus dismissal of all
mouse cancer models as irrelevant is unwarranted. Human can-
cers are enormously complex, and their evolutionary etiology
generates vast diversity amongandwithin them, thus challenging
the attainment of successful treatments. However, as knowledge
of cancer complexities has increased, so has the ability to design
mouse models that better represent cancer patients. PDX and
GEMmodelsdevelop tumorswith thegreatest similarity to human
diseases yet achieved, and the past 5 years have seen an in-
crease in their employment in preclinical research. As with all
models, eachapproach has its strengths and limitations (Table 1).
Early studies suggest promise for improved guidance in the
development of successful clinical treatments (Table 2), and
yet also emphasize the need for further scrutiny and refinement.
The following provides a balanced consideration ofmodel advan-
tages and limitations, their ramifications in obtaining optimally
accurate preclinical data, and the logistical requirements for
achieving efficiency, accuracy, and reproducibility.
Patient-Derived Xenograft Models
Relative toCDXmodels, immunocompromisedmicebearingsub-
cutaneoussurgically derivedclinical tumor samples (PDXmodels)
arebetteralignedwithhumandisease, since intact tissue thatpre-
serves tumor architecture is transferred directly to recipient mice
and not compromised by in vitro adaptation (Figure 2). PDXs are
the only models harboring bona fide tumor targets directly from
the patient, and hence their use in drug discovery is expanding
rapidly. Promise for suchmodels, first developedbyFiebig (Fiebig
et al., 1984), was demonstrated when chemotherapeutic agents,
such as alkaloids and anti-metabolites, were shown to elicit
similar responses in mice and patients (Mattern et al., 1988). In
contrast, a study of responses to numerous cytotoxic agents in
NCI60-basedCDXmodels showed that thepredictive value for ef-
ficacy was much less impressive (Johnson et al., 2001). Unfortu-
nately, early studies utilizing PDXs were limited by difficulties in
collecting clinical samples and in achieving sufficient take rates.
The recent resurgence of PDX model use for therapeutic eval-
uation has been fueled by significant improvements in clinical
sample access and transplantation technology. Cancers estab-
lished as PDXs can, in early passages, retain the stromal compo-
sition and histologic and molecular heterogeneity characteristic
of those in patients (Hidalgo et al., 2014; Tentler et al., 2012).
Since these properties critically impact therapeutic responses
and biomarker specificity, PDX models provide a preclinical
venue for addressing some of the most challenging barriers to
successful patient therapy. Furthermore, human target speci-
ficity allows for direct evaluation of lead human-specific thera-
peutics, such as antibodies, in clinical development.
Methodologies for PDX establishment and characterization are
detailedelsewhere (Hidalgoet al., 2014;Tentler et al., 2012;Zhang
et al., 2013). For some cancers, such as certainmelanomas, lung,
and colorectal cancers, transplant take rates can reachR75%,
and the time required for tumor growth can be as little as
2–4 months. However, these attributes vary widely depending
on sample type and amount (e.g., fresh biopsy tissue, fine needle
aspirate, circulating tumor cells), tumor origin, molecular proper-
ties, and recipient strain (see Supplemental Information).
Figure 3. Timeline of Key Preclinical Cancer
Model Developments since 1950
As the conceptual targets of cancer treatment
progressed from actively dividing cells to onco-
genic signaling and immune checkpoints, pre-
clinical models (right side) and cancer therapies
(left side) co-evolved accordingly. This evolution
was highly dependent on technical advances, re-
sulting in waves of activity. For example, recent
development of fully immunocompromised mice
and diverse syngeneic GEM models has signifi-
cantly promoted PDX and GDA models, respec-
tively, for preclinical cancer studies (the bracket).Consequently, some cancers, such as neuroendocrine, luminal
ER+breast, andprostatecancers (Rosfjordet al., 2014) areunder-
represented. Notably, PDX engraftibility appears to significantly
correlate with clinical aggressiveness (Ilie et al., 2015).
Relative to subcutaneous transplants, cancers orthotopically
transferred into organs of origin are more likely to maintain tumor
microenvironment characteristics that impact therapeutic out-
comes (Talmadge et al., 2007). However, orthotopic PDX pro-
duction is technically challenging, and, for most cancer types,
tumor growth and responses must be monitored via expensive
and often laborious longitudinal imaging. Thus, preclinical thera-
peutic studies currently exclusively utilize subcutaneousmodels.
Production of PDX cohorts is by serial tumor transplantation,
and, given the likelihood of changewith each passage, therapeu-
tic studies are most representative in low-passage models.
Additionally, human stromal components are maintained for
only 2–3 passages, with mouse stromal elements becoming
dominant thereafter (Rosfjord et al., 2014). Unfortunately, if
limited to early passage use, each model represents a limited
resource. Hence, most preclinical studies utilize models that
have been expanded, banked, and developed into significantly
sized cohorts. The extent of sacrifice in accurately predicting
efficacy is presently undefined and likely depends on the mech-
anism of therapeutic activity. As such, in propagating PDXs,
parental tumor traits should be routinely monitored, and devia-
tions must be considered in interpreting therapeutic and
biomarker data.
To circumvent immune rejection, human cancers must be
transplanted into immunocompromised mice. Commonly used
recipients, such as nude, SCID, and NOD/SCID strains, vary in
the extent of immune impairment (detailed in Supplemental
Information). IL-2Rg-deficient NOD/SCID mice (NSG and NOG
strains) are the most severely impaired, and often yield improved
take rates. Critically, the requirement for immunocompromisedCell 163, Shosts precludes assessment of arising
therapies designed to modulate immune
function (e.g., immune checkpoint inhibi-
tors a-CTLA-4, a-PD-1, a-PD-L1). More-
over, therapeutic responses in general
are likely influenced by preexisting can-
cer-dependent immune phenotypes and
immune responses elicited upon ther-
apy-induced tumor perturbation (Zitvogel
et al., 2008). The extent to which compro-mised immune systems limit predictive value for a given thera-
peutic approach will be determined as comparisons between
PDX and clinical outcomes are expanded. Technologies to
‘‘humanize’’ the mouse immune system by transplanting purified
human CD34+ hematopoietic stem cells into myeloablated
NSG/NOG recipients (e.g., ‘‘BLT’’ mice: http://jaxservices.jax.
org/invivo/humanized-BLT-mice.html) and other chimeric stra-
tegies have been developed (Legrand et al., 2009; Shultz et al.,
2014). However, the high cost of recipient mice, limitations on
human bone marrow acquisition, engraftment variability, and
technical demands currently preclude use of these models in
preclinical therapeutic discovery.
Despite the challenges to routine preclinical application,
several PDX studies have proven effective in paralleling human
outcomes (Malaney et al., 2014), in exploring drug resistance
mechanisms (Das Thakur et al., 2013) and in identifying targets
for second-line treatment (Girotti et al., 2015). Programs are
also underway to employ PDXmodels in individualized precision
cancer care. To date, this approach has been most successfully
applied to pediatric patients with advanced sarcomas who have
demonstrated the predicted response, sometimes to drugs not
previously associated with this indication (Tentler et al., 2012).
Patient-specific studies are currently limited by expense and
relatively long and unpredictable times for establishing test ani-
mals. Since current clinical trials generally involve patients who
have undergone prior failed treatments, results may not always
be obtainable in a beneficial timeframe.
Genetically Engineered Mouse Cancer Models
Of all murine cancer models, GEMs provide the most complete
representation of cancer development; cancers develop from
initiation through progression, co-evolve with intrinsic stroma,
and possess an intact immune system (Figures 1 and 2). How-
ever, GEM models are the most challenging to work with effec-
tively, and species differences must be carefully considered ineptember 24, 2015 ª2015 Elsevier Inc. 43
Table 2. Representative Clinically Relevant Mouse Trials
Tr esign Cancer Type Model Type Engineered Drivers Drugs/ Treatment Significance Relevant Publications
Pr inical Hematopoietic
(APL)
GEM PML-RARa fusion
PLZF-RARa fusion
Retinoic acid Demonstrated the efficacy of retinoic
acid plus As2O3 in specific APL
subtypes, validated in clinic
(Ablain and de The´, 2014;
Pandolfi, 2001)
Pr inical Pancreas
(Neuro-endocrine)
GEM RIP1-Tag2 Sunitinib Demonstrated the efficacy of Sunitinib
plus Imatinib, validated in clinic. FDA app d
for pancreatic cancer treatment in 2011.
(Pietras and Hanahan, 2005;
Raymond et al., 2011)
Pr inical Medulla-blastoma GEM Ptc1+/
P53/
GDC-0449
(SMO inhibitor)
Demonstrated the efficacy of an Shh
pathway small molecule inhibitor,
validated in clinic
(Romer et al., 2004;
Rudin et al., 2009)
Pr inical Pancreas
(Neuro-endocrine)
GEM RIP1-Tag2 Erlotinib
Rapamycin
Demonstrated efficacy of combining
drugs targeting EGFR and mTOR
(Chiu et al., 2010)
Co linical Pancreas
(PDA)
GEM LSL-KrasG12D
LSL-Trp53R172H
Pdx-1-Cre
Gemcitabine
Nab-Paclitaxel
Provided mechanistic insight into clinical
cooperation between Gemcitabine and
Nab-Paclitaxel
(Frese et al., 2012;
Goldstein et al., 2015)
Co linical Pancreas (PDA) GEM LSL-KrasG12D
LSL-Trp53R172H
Pdx-1-Cre
CD40 monoclonal
antibody Gemcitabine
Demonstrated that targeting stroma was
effective in treatment of metastatic PDA
(Beatty et al., 2013)
Co linical Lung
(NSCLC)
GEM KRASG12D
p53fl/fl
Lkb1fl/fl
Selumetinib
Docetaxel
Validation of improved response
of adding Selumetinib to
Docetaxel treatment
(Chen et al., 2012;
Ja¨nne et al., 2013)
Co linical Lung
(NSCLC)
GEM EML4-ALK fusion Crizotinib
Docetaxel
Pemetrexed
GEM model predicted clinical outcome
of drug combinations
(Chen et al., 2014;
Lunardi and
Pandolfi, 2015)
Co linical Various Sarcomas PDX N/A Various chemotherapies PDX testing predicted clinical outcome
of drug combinations
(Stebbing et al., 2014)
Po linical Ovarian
(SEOC)
GDA;
PDX
RB/p53-deficient
BRCA1/2-deficient
Olaparib
Cisplatin
Validation of treatment efficacy in BRCA
mutant tumors in both GDA and
PDX models
(Kortmann et al., 2011;
Szabova et al., 2014)
Po linical Pancreas
(Neuro-endocrine)
GDA RIP1-Tag2 Anti-VEGFR1 and
anti-VEGFR2 antibodies
Identification of mechanisms of resistanc
to anti-angiogenic therapies
(Casanovas et al., 2005)
Bi arker Lung
(NSCLC)
GEM;
Carcinogen-
induced
Various Models N/A Used in-depth quantitative MS-based
proteomics to profile plasma proteins
(Hanash and Taguchi, 2011)
Bi arker Pancreas (PDA) GEM KrasG12D
Ink4a/Arffl/fl
Pdx-1-Cre
N/A Used in-depth proteomic analyses to
identify candidate markers applicable
to human cancer
(Faca et al., 2008)
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experimental designs and interpretations. Extensive experience
and infrastructure are required to ensure the use of optimally
accurate models and to achieve sufficiently populated well-
controlled preclinical studies. Yet, GEM cancer models provide
the only opportunity to evaluate drug delivery, therapeutic
response, and biomarker expression for cancers evolving within
their natural microenvironment (autochthonous cancers). These
complex dynamic processes contribute to overall disease
properties, and in particular, constitute a source of the inter-
and intra-tumoral heterogeneity that challenges successful
therapeutic development. Additionally, the accuracy of some
therapeutic interventions, such as those targeting the immune
system, may depend on the constitution of evolutionary, rather
than transplanted, disease. Indeed, overall, GEMs and GEM-
derived models are currently the only preclinical platform for
evaluation and optimization of immunomodulatory therapies.
Although some immune properties differ in mouse and human,
there is significant conservation (Bailey et al., 2013); moreover,
many differences can be managed via data interpretation or
minimized by using genetically engineered ‘‘humanized’’ models
(Scheer et al., 2013). Finally, autochthonous GEMs are the only
viable models for evaluating prevention therapies.
Several reports show that well-designed GEM studies can
contribute to improved clinical trials (Table 2), not only in identi-
fying potentially efficacious therapies but also in predicting both
positive and detrimental effects inmolecular subclasses. Amajor
power of GEM approaches is in the flexibility to create models
with precise molecular specificity. With increasing sophisticat-
ion, several strategies (summarized below and detailed else-
where [Abate-Shen et al., 2014]) have been employed over the
past three decades to significantly enrich our understanding of
cancer mechanisms. A plethora of genes frequently altered in
human cancers have been validated as disease drivers in
GEMs, thereby facilitating the evaluation of cancer evolutionary
mechanisms and kinetics, susceptible cell and molecular
targets, relative cancer cell and microenvironment roles, and
mechanisms of invasion and metastasis. Indeed, entire natural
disease histories can be mapped (Stiedl et al., 2015; Van Dyke
and Jacks, 2002).
In the process of basic discovery, countless GEM cancer
models representing a variety of histiocytic cancer types driven
by multiple independent drivers have been produced, and
many are currently used in preclinical evaluations. Although no
model can perfectly capture the human condition, several
GEM models tractable for preclinical studies develop cancers
with remarkable molecular and pathologic similarity to their
human counterparts. However, since most established GEMs
were created to address basic mechanisms, many do not accu-
rately model human disease and/or are intractable for effective
preclinical evaluation. Furthermore, each engineering approach
can elicit untoward anomalies. Such circumstances can be
accommodated in the interpretation of mechanistic studies,
but are the basis for exclusion of many models for effective pre-
clinical research. Thus, choosing appropriate models as sub-
jects for preclinical discovery requires a deep understanding of
cancer biology and genetics and also of engineering modalities.
The following provides a reasonable guide for optimizing the
value of GEM-based preclinical platforms.Germline GEMs
An extensive array of technologies is employed to engineer the
mouse germline with great precision. By editing the genome of
embryonic stem (ES) cells or zygotes, mice can be programmed
for cell-type-specific disruption of tumor suppressor genes via
direct mutation or expression of interfering non-coding RNAs
(RNAi) (Walrath et al., 2010) and for oncogene expression at
physiological or cancer-analogous levels. Furthermore, mice
can be ‘‘humanized’’ by engineering the expression of drug tar-
gets in relevant cell types (Scheer et al., 2013) so that human-
specific targeted therapies, such as antibody-based drugs,
can be tested in GEM models. While traditional methods for
constructing locus-specific genetic changes require significant
lead times for engineering, the recent development of rapid
sequence-targeted approaches (Mou et al., 2015) has signifi-
cantly reduced this time to weeks instead of many months. In
particular, clustered regularly interspaced short palindromic re-
peats (CRISPR)/Cas9 technology, which is efficient and versa-
tile, is accelerating germline engineering and also facilitating
rapid somatic engineering (see below).
Depending on the strategy, expression of an engineered
‘‘event’’ can be constitutive or inducible, although gene induction
with cell-type and temporal specificity provides the best possibil-
ity for accurately modeling disease development. Inducibility is
achieved by combining cell-specific expression of transcription
factors (e.g., doxycycline-modulated tet-transactivators) or re-
combinases (Cre-lox or Flp-FRT) with cognate cis elements
linked to a target gene, or by expressing proteins fused with a
hormone-responsive domain (e.g., the tamoxifen-inducible
estrogen receptor domain) (see Supplemental Information).
When multiple distinct inducible systems are combined within
the same cancer model, cancer-specific mutations can be
induced sequentially in order to map and emulate cancer
evolution (e.g., [Young et al., 2011]) and thus to generate increas-
ingly relevant preclinical models. Reversible inducibility can be
achieved with each of these technologies, although small
molecule-mediated modulation of transcription factors and hor-
mone-responsive domains are the most tractable for toggling
expression on and off (Abate-Shen et al., 2014; Texido´, 2013).
This approach facilitates the identification of events required
to sustain tumor growth (‘‘oncogene addiction’’) (e.g., Soucek
et al., 2008) and thus of potential therapeutic targets (e.g., Kwong
et al., 2012). Tumor responses to the shutdown of oncogenes or
restoration of functional tumor suppressors within tumors, or
appropriate effector cells, indicate the potential efficacy of
targeted therapies, while genetic ablation in the entire animal
predicts the overall toxic effects of specific inhibitors. How-
ever, since off-target effects will not register in this approach,
results only indicate whether a given therapy is potentially
efficacious.
A critical, often overlooked, consideration when building
GEMcancermodels is the incorporation of known environmental
etiologies. However, there are notable examples wherein certain
environmental factors were validated as etiologic agents and
thus produced representative cancer models, including HPV
E6/E7-induced cervical cancer (Riley et al., 2003), UV acceler-
ated melanomas (BRAFV600E [Cao et al., 2013], mutant
HRAS [Kannan et al., 2003], and HGF/MET [Noonan et al.,Cell 163, September 24, 2015 ª2015 Elsevier Inc. 45
2001] models), and Helicobacter-fueled gastrointestinal cancers
(Rogers and Fox, 2004). Exposure of GEM cancer models to
environmental mutagens can be used to approximate the muta-
tion load of many human cancers (e.g., Westcott et al., 2015),
which influences therapeutic outcomes such as in drug-resistant
relapse and neoantigen load-dependent immunomodulation.
The extent to which findings in GEMs extend to patients
depends on engineering mice based on our understanding of
human cancer etiologic drivers, cellular origins, heterogeneity,
pathogenesis, andclinical properties. To recapitulate humancan-
cer development, clinically relevant driver gene(s) or pathways
must be perturbed in relevant target cells. For adult cancers,
gene expression should be targeted to adult, rather than devel-
oping, organs. Furthermore, for optimalmodeling, cancers should
progress ina relevant sequence, since theorderof events impacts
properties of evolving tumors. Ideally, both initiation and progres-
sion to aggressive cancer should be evaluated using individual
and relevant combinations of molecular aberrations thought to
be causal in humans. High phenotypic penetrance and consis-
tency among animals within a lineage are essential for tractability.
The accuracy of disease modeling depends on actually
achieving the specificity envisioned in experimental designs,
which is not always realized because of technical limitations
and/or gaps in current knowledge. Of course, engineered se-
quences must be validated, but it is also critical that expected
transcriptional specificities be confirmed. Unless targeted to
specific genomic locations, transgenes insert randomly, and
expression can be dramatically altered depending on insertion
sites. Furthermore, transgenes may not carry all necessary
regulatory signals. Hence, several founder lines should be estab-
lished and fully characterized before selecting accurate repre-
sentative lines for modeling cancers. Even targeted genetic
changes have the potential to alter gene regulation. Thus, spec-
ificity, levels, and range of expression must be evaluated
for each model; aberrant expression usually alters disease and
can also yield ectopic phenotypes that hinder tractability and
invalidate data. Yet, a surprising number of existing engineered
strains, including those driving inducible expression, are not
fully characterized. Hence, when choosing cancer models for
preclinical studies, it is essential that expression and disease
patterns are well established and accurately represented (see
Supplemental Information).
Non-Germline GEM Models
While autochthonous GEM models have great utility, most are
not tractable for large-scale screening of multiple anti-cancer
drug candidates due to high cost, long timelines, extensive com-
plex breeding, and/or difficulties in obtaining synchronous
tumorigenesis. Preclinical analysis of metastatic lesions is
particularly challenging; primary tumors arise stochastically
with no reliable timetable, as in humans, and multiple tumors
often develop. Thus, extensive longitudinal tomographic imaging
is required to enroll mice bearing similarly sized tumors for ther-
apeutic evaluation (e.g., Weaver et al., 2012). Such procedures
require specialized expertise and can be too expensive and
time-consuming for first-line drug screening. Several strategies
to produce ‘‘non-germline’’ GEMs have been developed that
bypass breeding, reduce expense, and, in some cases, improve
flexibility, uniformity, and timelines (Heyer et al., 2010).46 Cell 163, September 24, 2015 ª2015 Elsevier Inc.GEM-Derived Allograft Models. GEM-derived allograft (GDA)
models marry the genetic and biologic human cancer similarities
of GEMmodels with the relative ease of transplantation technol-
ogy of PDXs (Heyer et al., 2010). Without in vitro manipulation,
tissue fragments derived from tailor-made GEM tumors are
expanded by transplantation, orthotopically or subcutaneously,
into immunocompetent syngeneic hosts (Figure 2). Thus, tumors
can be banked to facilitate large cohort production, and efficacy
studies can be performed in industry-friendly timeframes (3–
8 weeks), allowing for increased throughput. Indeed, a battery
of treatments can be evaluated in GDAs prior to (preclinical)
or parallel with (‘‘co-clinical’’) clinical trials (Table 2). As with
GEMs, immune systems are fully functional in GDAs, and inter-
actions among tumor cells and their intrinsic microenvironments
are maintained.
GDAs are particularly amenable to the evaluation of metastatic
disease, which is responsible for most cancer-related deaths
and is rarely assessed preclinically. In GDAs, metastases occur
from single primary tumors, which can be resected to allow time
for metastatic progression (Day et al., 2012). This approach also
emulates clinical care standards for many cancers and facilitates
comparing therapeutic responses of both primary and metasta-
tic disease derived from the same GEM cancer (Figure 4).
As with PDXs, serial passaging increases the likelihood that
tumor properties will deviate from parental samples due to
further evolution and/or selection of sub-compartment growth;
thus, transplanted tumors should be monitored for molecular
and biological similarity to founding tumors. Additionally, since
transplanted tumors do not evolve in situ, GDAs cannot legiti-
mately be used for prevention studies, and some therapeutic
outcomes may differ between autochthonous GEMs and
GDAs. Given the potential tradeoff of accuracy for tractability,
candidate therapies efficacious in GDAs should be subse-
quently validated in the original GEM models prior to clinical
studies.
Stem Cell-Derived Chimeras and Somatic Models. Mice
chimeric for genetically engineered cells are created through
implantation of GEM-derived or genetically manipulated ES cells
into pre-implantation embryos. Since oncogenic alleles are engi-
neered ex vivo in ES cells, many mice with the desired genetic
composition can be generated in the absence of complex, labo-
rious, and long-term breeding schemes. The potential value of
this approach was first highlighted in the production, analysis,
and preclinical evaluation of lung adenocarcinoma (Zhou et al.,
2010). Once constructed, ES cells harboring the desired alleles
can be derived from blastocysts produced by a penultimate
cross. In turn, this bankable resource can be used to generate
mice chimeric for mutant and wild-type cells (Premsrirut et al.,
2011), facilitating conditional RNAi-mediated knockdown of
target expression via manipulation of ES cells, which can then
be used to generate chimeric mouse cohorts (Dow et al., 2012).
Notably, the advent of CRISPR/Cas9 technology, and with it
the ability to perform complex gene editing with relative ease
and speed, has dramatically enhanced the value of non-germline
GEMapproaches. Several groups have precisely modified onco-
genes and tumor suppressor genes directly in somatic cells of
adult mice, significantly improving the feasibility and flexibility
of this genetic engineering approach (Chen et al., 2015; Dow
Figure 4. Generation and Application of
Metastatic GDA Models
(I) GDAs are derived from tumors arising in mice
genetically tailored to produce human-relevant
models. Relevance can be further enhanced by
including appropriate etiological agents (lighting
bolt). Arising tumors are resected, labeled with
imageable markers (green), and directly trans-
planted into fully immunocompetent syngeneic
mice at either subcutaneous or orthotopic sites.
The imageable markers allow monitoring of tumor
growth and drug response, and/or FACS purifi-
cation for analysis. Once successfully trans-
planted, GDAs can be expanded for banking and/
or preclinical studies. Mice bearing GDAs can be
treated directly with individual or combination
drugs (*) to study therapeutic efficacy at the ‘‘pri-
mary’’ tumor site (II). (III and IV) Alternatively, GDAs
can be resected using survival surgery, and
treatments focused on metastatic disease, simu-
lating first-line treatment in human patients
following primary tumor resection. GDA models
allow for interventive treatment of metastatic dis-
ease once detected (III), or preventive adjuvant
treatment initiated immediately following surgical
resection (IV). GDAmodels are thus well suiting for
studying primary or metastatic disease, with in-
terventive or preventive approaches using
pathway-targeted small molecule and/or immu-
notherapeutic agents.et al., 2015; Maddalo et al., 2014; Platt et al., 2014). These
models also better mimic human cancer relative to standard
germline GEMs in that tumors typically arise from fewer cells in
the context of normal stroma
In a variation of the non-germline GEM approach, genetically
engineered stem or progenitor cells can be transplanted into
syngeneic mice, where they can home to appropriate tissue
targets and become the cells of origin for developing tumors
(Heyer et al., 2010). These models are especially amenable for
studying hematopoietic cancers, where the stem cells are well
characterized and the host can be prepared for receiving trans-
planted cells by using irradiation to create a favorable niche for
the engineered hematopoietic stem/progenitor cells to colonize.
Successes have also been reported for other cancers (Heyer
et al., 2010).
Logistics for Optimizing Preclinical Studies
Extensive complexities that impede successful drug develop-
ment in cancer patients dictate that faithful murine cancer
models must themselves be complex. Both PDX- and GEM-
based models offer this opportunity. However, their very com-
plexity warrants that informative models are generated and
characterized with substantial knowledge of cancer mecha-
nisms and modeling limitations, rigorous animal maintenance
and production, routine phenotypic and genetic monitoring,
appropriate strategies for therapeutic response evaluation,
and consideration of multiple variables that impact data interpre-
tation. To achieve routine therapeutic and biomarker develop-
ment that positively influence patient care, preclinical studies
must be (1) well-powered with significant cohort sizes and
several evaluation parameters, (2) goal-oriented and efficiently
executed, and (3) highly reproducible.Experimental Considerations
Once models that optimally represent human disease have
been selected, clinical relevance relies on experimental param-
eters that are comparable and/or translatable to human prac-
tice. These include, but are not limited to, dosing levels and
schedules, drug pharmacology, response evaluation methods,
and endpoint choices. Therapeutic agents’ pharmacokinetics
(PK) and ability to modify targets when known (pharmacody-
namics; PD) should be measured in tumor-bearing mice. The
fate of administered drugs is largely determined by drug
metabolizing enzymes essential for their absorption, distribu-
tion, metabolism, and excretion (ADME). Therefore, the differ-
ences that exist between the central metabolizing enzymes in
mice and humans, the cytochrome P450 (CYP) family, consti-
tute a confounding factor in extrapolating drug PKs and the re-
sponses they elicit. Since the maximum tolerated dose (MTD)
of many drugs in mice is significantly higher than in humans,
it is essential to evaluate efficacy by using doses achievable
in patients. However, this is possible only when human PKs
are known; for example, for repurposing FDA-approved
drugs, for preclinical evaluation of combination therapies that
comprise single phase II agents, and for co-clinical experimen-
tation wherein mouse and human evaluations are performed in
parallel, such that clinical toxicity results are available. Even
when appropriate human dosing is known, there is no simple
formula for approximating comparable doses to achieve the
same PK in mice, and instead experimental determination is
required (Sparreboom et al., 1996). Yet, when evaluating
numerous agents, this approach is not possible; rather, subse-
quent coordination of clinical results and further preclinical
dose escalation experiments are needed for optimal response
assessment.Cell 163, September 24, 2015 ª2015 Elsevier Inc. 47
In an effort to apply a genetic solution to the PK problem, a
number of humanized CYP GEMs have been developed (Gonza-
lez, 2004; Scheer and Wolf, 2014). Despite these advances, the
humanized alleles have not yet been incorporated into GEM can-
cer models or PDX recipients. Such an undertaking will require
significant resources, substantial time, and community effort to
generate and evaluate revised models. Nonetheless, the invest-
ment will be worthwhile if the gap between laboratory mice and
patients is narrowed.
The choice of preclinical experimental endpoints to deter-
mine therapeutic responses is also critical for achieving out-
comes most representative of those in patients (Talmadge
et al., 2007). In prevention studies, efficacy is based on dis-
ease-free or minimized status. For intervention therapy, efficacy
is justified by overall survival and should not be judged solely
on tumor growth inhibition. The importance of survival end-
points is highlighted by a pancreatic cancer clinical trial de-
signed based on short-term GEM studies demonstrating
reduced tumor volumes in response to sonic hedgehog
pathway inhibition combined with gemcitabine (standard of
care) compared to gemcitabine alone (Olive et al., 2009). Unfor-
tunately, the trial terminated early due to increased disease
dissemination and poor patient survival. However, subsequent
survival studies in the GEM model replicated the clinical result,
demonstrating that initial drug effects did not predict survival
outcomes. Hence, the model appropriately predicted patient
responses, but only with a meaningful endpoint (Couzin-
Frankel, 2014).
Tumor growth and therapeutic responses in subcutaneous
transplant models, such as CDXs, PDXs, and GDAs can be
monitored by standard caliper measurement. Tumor growth in
autochthonous and orthotopic transplant models (other than
skin and breast models) and in all metastatic models must be
monitored by longitudinal imaging strategies (Wang et al.,
2015). High-resolution 3D images are compiled from sectional
images generated by tomographic scanning of signals from
X-ray (CAT), magnetic field-excited atoms (MRI), or injected
radioactive tracers (SPECT; PET) (Supplemental Information).
Tomographic imaging requires specific expertise for accurate
execution and is relatively expensive and time-consuming. Opti-
cal imaging, which detects visualized wavelengths generated
from excited fluorescent chromophores (e.g., jellyfish GFP) or
firefly luminescent reactions (e.g., luciferase), can be employed
for detection in real-time and is cost- and time-effective; how-
ever, these methods do not produce accurate tomographic
data and are limited by tissue absorption. Notably, traceable
marker proteins required for optical imaging are xenogeneic
with respect to mammals and can induce immune responses
in immunocompetent mice, which can result in inconsistent
activity, graft rejection and/or inhibition of metastasis, confound-
ing data interpretation. Hence, effective employment of xenoge-
neic reporters is restricted to short-term studies or studies in
immunocompromised models, limiting their usefulness in pre-
clinical science (Steinbauer et al., 2003). However, this problem
can be circumvented, at least in part, by employing host mice
genetically engineered to express respective markers at an early
age, which elicits tolerance and thus recognition as ‘‘self’’ (Day
et al., 2014).48 Cell 163, September 24, 2015 ª2015 Elsevier Inc.Several additional points associated with preclinical trial
design are worth emphasizing. Tumor mass is a critical factor
in preclinical studies; vastly different outcomes can result from
initiating drug dosing when tumors are different sizes. Moreover,
human tumors are typically much larger than their mouse
counterparts, which could affect how preclinical data translates
to the clinic. It is also vital to run preclinical trials with a sufficient
number of animals in each experimental arm to achieve statis-
tically significant results; ensuring statistical power must be
considered a priority for any preclinical study. Therefore, it is pru-
dent to consult biostatisticians prior to finalizing study designs.
Finally, the influence of genetic background on tumor behavior
can be significant, and must be considered when designing
model systems. Generation and analysis of mouse cancer
models within the collaborative cross, a large panel of inbred
mouse strains (Churchill et al., 2004), could also provide impor-
tant insights into the impact of complex germline genetics on
tumor predisposition and drug response.
Infrastructure
Critical work establishing the utility of murine cancer models in
preclinical research has taken place in independent laboratories
over the last 20 years. However, because of severe resource lim-
itations, the absolute need to perpetuate basic investigator-
driven mechanistic discovery, and an increasingly competitive
environment wherein success is measured by individual merit,
the opportunity for laboratories to execute preclinical studies
beyond the pilot level is limited. Recent reports indicate that
most preclinical outcomes at this level are not reproduced
when studies are not conducted with robust experimental stan-
dards, such as inclusion of appropriate positive and negative
controls, execution with sufficient statistical power, attention to
pharmacological considerations, and implementation of blind
evaluations (Begley and Ellis, 2012; Begley and Ioannidis,
2015). Adherence to all these standards is simply not possible
in individual laboratories under current conditions. To increase
accessibility to preclinical evaluation in murine cancer models,
several institutions have established core facilities that perform
studies using dedicated staff and common methodologies.
These cores represent a necessary step to improve reproduc-
ibility in preclinical outcomes. Yet, most core facilities do not
have the resources to instate the full range of skills and technol-
ogies indicated in ‘‘Experimental Considerations’’ above to
ensure optimal quality and replication of clinical approaches.
Additionally, conducting well-powered blinded studies requires
a sizable dedicated staff, which is generally not achievable in ac-
ademic cores. Finally, global improvement of murine preclinical
research must include the generation of an increased range of
well-characterized, technically tractable and optimally accurate
models vetted for preclinical evaluation, along with the develop-
ment of exportable standard operating procedures (SOPs).
To address these needs, over the past decade several orga-
nized efforts have been established that are dedicated to: (1)
improving the accuracy and reproducibility of preclinical drug
development platforms; (2) developing and exporting SOPs
and models; (3) understanding cancer pathobiology through
targeted therapeutics; and/or (4) applying the outcomes of opti-
mized preclinical therapeutic and biomarker studies to clinical
research for improved patient care. Common attributes in each
Table 3. Future Challenges and Possible Solutions for Mouse Preclinical Cancer Trials
Issue Challenges Possible Solutions
Model improvement More precise spatial and temporal control
of genetic alterations in mouse tissues
Improve technologies for genomic editing
(e.g., CRISPR) and regulating gene activity
Human relevance of stroma, immune system,
and therapeutic targets in mouse cancer models
‘‘Humanize’’ genes via genetic engineering
and immune system by reconstitution
with human hematopoietic stem cells
Recapitulation of the tumor heterogeneity
found in human cancers
Introduce environmental etiological factors
(e.g., UV in skin cancer models); allow tumor
evolution by avoiding inappropriately
dominant oncogenic drivers
Study setting Difficulties in diagnosis and treatment of large
cohorts of mice as individual patients
Synchronize tumorigenesis by adopting
inducible GEM or transplantable GDA systems
Disease progression and clinically relevant
endpoints in preclinical study
Improve biomarkers and imaging techniques
for tumor tracking; adopt clinically relevant
endpoints (e.g., progression-free survival)
Integration of pathologic, genomic, bioinformatic,
molecular, and immunological analyses
Develop/share improved and standardized
protocols; organize workflows with core facilities
Extrapolation to
human disease
Evaluating effects of life style on therapeutic outcomes Consider gender, diet, and exposure to
environmental factors in protocol development;
consider effects of microbiota
Physiological difference between mouse and human ‘‘Humanize’’ aspects of mice; consider scaling
law in PD/PK, lifespan, hemodynamics, etc.case include: (1) a sufficient number of dedicated staff covering a
broad range of expertise; (2) access to sophisticated instrumen-
tation and technology for a full range of small animal imag-
ing modalities, histological and molecular pathology, genomic
technologies, pharmacological methods, model generation,
and appropriate maintenance and quality control for a large
‘‘bank’’ of models; and (3) data management strategies. Exam-
ples of such organizations include the Center for Advanced Pre-
clinical Research (CAPR; Center for Cancer Research, National
Cancer Center and the Frederick National Laboratory for Cancer
Research, https://ccr.cancer.gov/capr-home); Mouse Clinic for
Cancer and Aging research (MCCA; Netherlands Cancer Insti-
tute and the European Research Institute for the Biology of
Aging, http://www.mccanet.nl/); Center for Co-Clinical Trials
(MD Anderson, http://www.cancermoonshots.org/platforms/
center-for-co-clinical-trials/); and the Co-Clinical Project: In-
forming Clinical Trials Using Preclinical Mouse Models (Harvard
Medical School). Similar efforts focused specifically on pancre-
atic ductal carcinoma include the Mouse Hospitals (Columbia
Medical School, http://www.olivelab.org/mouse-hospital.html,
and Cold Spring Harbor Laboratories).
Emerging and Future Prospects
This PRIMER focuses on the attributes and limitations of murine
cancer models that currently best emulate our existing under-
standing of human cancers, an ever-expanding awareness of
which is required to drive development of effective preclinical
platforms. The high cost and low yield of efficacious therapies,
despite clinical evaluation of countless potential therapeutics,
motivate the use and development of preclinical PDX and GEM
in the guidance of clinical research. Ultimately, collective
employment of a variety of model systems will likely be required
to successfully impact clinical outcomes.Optimal mouse studies are sufficiently cumbersome so as to
preclude the simultaneous evaluation of numerous drugs and
unbiased libraries; high-throughput in vitro screening systems
are essential precursors to in vivo evaluations. Despite their lim-
itations, cancer cell lines have proven valuable in uncovering
mechanisms of acquired drug resistance for in vitro drug screens
(Torrance et al., 2001), and several technologies such as RNAi
and CRISPR/Cas9 methods have enhanced their versatility
(Corcoran et al., 2013; Shalem et al., 2014). However, cancer
cell-line screens identify only drugs that target intrinsic cancer
cell functions. Targeting tumor stroma or microenvironment/
tumor cell interactions requires the use of in vitro systems that
approximate the composition of cancers that preserve important
cancer constituents, cell-cell interactions, and architectural
features. To this end, several ex vivo platforms have been devel-
oped, including spheroids, organoids, microtumors (tumor tis-
sue in synthetic matrix), and tissue slices (Burdett et al., 2010;
Mendoza et al., 2010; Yamada and Cukierman, 2007). While
optimization and validation of emerging ex vivo models in drug
screening is ongoing, many may be incorporated into early
phases of drug development, resulting in efficient triage and
increased success in vivo.
In addition to ex vivo systems, non-murine whole organism
drug screens have shown promise for early triage (Gao et al.,
2014). Due to their relatively small size, low cost, and high fecun-
dity, invertebrates such as flies (Drosophila) and nematodes
(C. elegans) have shown promise. Furthermore, zebrafish (Danio
rerio) are particularly well suited for high throughput screens
because of rapid extra-uterine development, embryonic trans-
parency, and recently developed pigment deficiency to facilitate
imaging (Barriuso et al., 2015). Using automated high content
and high throughput platforms, zebrafish can be used for chem-
ical, genetic, and pathway-based screens (Lieschke and Currie,Cell 163, September 24, 2015 ª2015 Elsevier Inc. 49
2007). Notably, data generated from zebrafishmodels have been
used in clinical trials. For example, the pyrimidine biosynthesis
enzyme DHODH was identified in zebrafish screens as a novel
melanoma drug target, and a clinical trial is underway in which
patients are being treated with the DHODH inhibitor leflunomide
(Hagedorn et al., 2014; White et al., 2011). Zebrafish have also
been used as hosts for human and mouse xenografts to monitor
invasiveness, angiogenesis, and drug responses in real time
(Zhang et al., 2015). However, as with xenotransplantation of
human cells into mice, inappropriate tumor-host interactions
could limit the relevance and translational value of fish models.
Optimization of preclinical models that can impact clinical
practice will require overcoming challenges in several arenas
(Table 3). However, achieving this goal will undoubtedly require
expansion and integration of organized efforts by many factions.
The sophistication of such preclinical studies requires expertise
inmanydisparate fieldsandnecessitates involvementof scientists
in the public sector, who often possess critical expertise
and mechanisms not available in the private sector. However,
communicationanddata-sharingamong investigatorsandorgani-
zations, though essential for efficient optimization of effective pre-
clinical standard operating procedures, are limited. A future prior-
ity will be to develop interactive web-based systems to house and
mine experimental databases and SOPs for community sharing.
Such organized initiativeswill begin tomeet the significant and im-
mediate need to revolutionize the accuracy of preclinical assess-
ment and to develop and utilize PDX- and GEM-based disease
models in research to increase the number of effective treatments
reaching clinical trials and thus, cancer patients.
In summary,wenowhave awealth ofmodel systems that show
early promise in establishing robust preclinical assessment plat-
forms for improving clinical success. Each system has specific
and sometimes unique value, and all will undoubtedly play a sig-
nificant role in varied aspects of future preclinical studies. At this
junction, systematic comparisons in the prediction of human out-
comes by distinct model systems has not been carried out and is
needed in order to construct sound preclinical operating princi-
ples. The selection of models for a given study will undoubtedly
depend on the required purpose.While 2D cell cultures are useful
for identifying cancer cell-intrinsic vulnerabilities, 3D ex vivo
methods incorporate assessment of multicellular interactions.
Non-mammalian animals further offer reasonable throughput in
complex biological systems,while PDXandGEMmodels provide
the best representation of tumor microenvironments, physiolog-
ical responses, and disease pathology. GEMs further allow for
evaluation of immune system interventions and of responses
unique to in situ developed disease. Ultimately, the complemen-
tary use ofmany of thesemodels and continual efforts to improve
their effectiveness will propel preclinical studies to a new era of
cancer therapeutics development. This is a uniquely exciting
era wherein preclinical models, rather than serving simply to
confirm clinical outcomes, have the potential to routinely fuel
optimized clinical success.SUPPLEMENTAL INFORMATION
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